🚀 VC round data is live in beta, check it out!
LigaChem Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for LigaChem Biosciences and similar public comparables like Corcept Therapeutics, Yuhan, Dianthus Therapeutics, Ligand Pharmaceuticals and more.
LigaChem Biosciences Overview
About LigaChem Biosciences
LigaChem Biosciences Inc develops new drugs through research. The Company provides business research services, manufacturing and sale of compounds, and drug evaluation.
Founded
2006
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$5B
LigaChem Biosciences Financials
LigaChem Biosciences reported last 12-month revenue of $110M and negative EBITDA of ($49M).
In the same LTM period, LigaChem Biosciences generated $101M in gross profit, ($49M) in EBITDA losses, and had net loss of ($31M).
Revenue (LTM)
LigaChem Biosciences P&L
In the most recent fiscal year, LigaChem Biosciences reported revenue of $96M and EBITDA of ($58M).
LigaChem Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $110M | XXX | $96M | XXX | XXX | XXX |
| Gross Profit | $101M | XXX | $85M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | ($49M) | XXX | ($58M) | XXX | XXX | XXX |
| EBITDA Margin | (45%) | XXX | (61%) | XXX | XXX | XXX |
| EBIT Margin | (47%) | XXX | (74%) | XXX | XXX | XXX |
| Net Profit | ($31M) | XXX | ($49M) | XXX | XXX | XXX |
| Net Margin | (29%) | XXX | (51%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
LigaChem Biosciences Stock Performance
LigaChem Biosciences has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
LigaChem Biosciences' stock price is $133.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | -0.6% | XXX | XXX | XXX | $-1.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLigaChem Biosciences Valuation Multiples
LigaChem Biosciences trades at 41.4x EV/Revenue multiple, and (92.9x) EV/EBITDA.
EV / Revenue (LTM)
LigaChem Biosciences Financial Valuation Multiples
As of April 18, 2026, LigaChem Biosciences has market cap of $5B and EV of $5B.
Equity research analysts estimate LigaChem Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LigaChem Biosciences has a P/E ratio of (154.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 41.4x | XXX | 47.4x | XXX | XXX | XXX |
| EV/EBITDA | (92.9x) | XXX | (77.7x) | XXX | XXX | XXX |
| EV/EBIT | (89.0x) | XXX | (64.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 45.2x | XXX | 53.3x | XXX | XXX | XXX |
| P/E | (154.9x) | XXX | (99.5x) | XXX | XXX | XXX |
| EV/FCF | (198.0x) | XXX | (108.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified LigaChem Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
LigaChem Biosciences Margins & Growth Rates
LigaChem Biosciences' revenue in the last 12 month grew by 44%.
LigaChem Biosciences' rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LigaChem Biosciences' rule of X is 134% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
LigaChem Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 44% | XXX | 55% | XXX | XXX | XXX |
| EBITDA Margin | (45%) | XXX | (61%) | XXX | XXX | XXX |
| EBITDA Growth | (112%) | XXX | (92%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 134% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 153% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 164% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
LigaChem Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| LigaChem Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Corcept Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Yuhan | XXX | XXX | XXX | XXX | XXX | XXX |
| Dianthus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ligand Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Dong-E-E-Jiao | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LigaChem Biosciences M&A Activity
LigaChem Biosciences acquired XXX companies to date.
Last acquisition by LigaChem Biosciences was on XXXXXXXX, XXXXX. LigaChem Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by LigaChem Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLigaChem Biosciences Investment Activity
LigaChem Biosciences invested in XXX companies to date.
LigaChem Biosciences made its latest investment on XXXXXXXX, XXXXX. LigaChem Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by LigaChem Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout LigaChem Biosciences
| When was LigaChem Biosciences founded? | LigaChem Biosciences was founded in 2006. |
| Where is LigaChem Biosciences headquartered? | LigaChem Biosciences is headquartered in South Korea. |
| Who is the CEO of LigaChem Biosciences? | LigaChem Biosciences' CEO is Yong-Ju Kim. |
| Is LigaChem Biosciences publicly listed? | Yes, LigaChem Biosciences is a public company listed on Korea Exchange. |
| What is the stock symbol of LigaChem Biosciences? | LigaChem Biosciences trades under 141080 ticker. |
| When did LigaChem Biosciences go public? | LigaChem Biosciences went public in 2013. |
| Who are competitors of LigaChem Biosciences? | LigaChem Biosciences main competitors are Corcept Therapeutics, Yuhan, Dianthus Therapeutics, Ligand Pharmaceuticals. |
| What is the current market cap of LigaChem Biosciences? | LigaChem Biosciences' current market cap is $5B. |
| What is the current revenue of LigaChem Biosciences? | LigaChem Biosciences' last 12 months revenue is $110M. |
| What is the current revenue growth of LigaChem Biosciences? | LigaChem Biosciences revenue growth (NTM/LTM) is 44%. |
| What is the current EV/Revenue multiple of LigaChem Biosciences? | Current revenue multiple of LigaChem Biosciences is 41.4x. |
| Is LigaChem Biosciences profitable? | No, LigaChem Biosciences is not profitable. |
| What is the current EBITDA of LigaChem Biosciences? | LigaChem Biosciences has negative EBITDA and is not profitable. |
| What is LigaChem Biosciences' EBITDA margin? | LigaChem Biosciences' last 12 months EBITDA margin is (45%). |
| What is the current EV/EBITDA multiple of LigaChem Biosciences? | Current EBITDA multiple of LigaChem Biosciences is (92.9x). |
| What is the current FCF of LigaChem Biosciences? | LigaChem Biosciences' last 12 months FCF is ($23M). |
| What is LigaChem Biosciences' FCF margin? | LigaChem Biosciences' last 12 months FCF margin is (21%). |
| What is the current EV/FCF multiple of LigaChem Biosciences? | Current FCF multiple of LigaChem Biosciences is (198.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.